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Tumor Endothelial Marker 1 (TEM1 or CD248) has
been identified as a microvascular marker of tumor
angiogenesis in various human cancers. By comparing
the vasculature of ovarian cancer and normal ovary, we
and others [1] identified that TEM1 is overexpressed in
tumor microenvironment in ovarian cancer and it could
be suggested as a suitable marker for targeting tumor
vasculature of cancer therapeutics. In addition, we also
confirmed that TEM1 is overexpressed in cancer cells in
most soft tissue sarcoma patients.
To better assist TEM1-specific theranostics, we sought
to develop TEM1-specific affinity agents. From previously
isolated TEM1-specific single chain antibody, scFv78 [2],
we developed a panel of new multivalent variants of
scFv78 to improve the thermal, serum stability and avidity.
The variants includes a dimeric Fc fusion (from hu IgG1),
a tetrameric CH2 fusion, a dimeric CH3 fusion and a
dimeric (Fab)2 fusion. This panel was produced using
mammalian cells and affinity purified from culture super-
natant. The protein of scFv78-Fc exhibited higher affinity
(KD = 0.14 ± 0.01nM, 15 fold higher of parental scFv78)
to the target protein in live cell ELISA assay. Using the
preclinical tumor vascular models we developed [3,4],
pharmacokinetics and biodistribution studies in revealed
that the scFv78Fc has extended serum half-life. Near infra-
red (NIR) immuno-imaging [5] and 124I-immunoPET
imaging with scFv78-Fc demonstrated that such tracers
were enriched in TEM1-positive tumors but not normal
organs. In addition, scFv78Fc was conjugated to Mono-
methyl auristatin E (MMAE) and saporin to develop
potent TEM1-targeting immunotoxins, which showed
TEM1-specific toxicity in vitro and in preclinical animal
models. Lastly, TEM1-targeted nanomedicine platform
was developed and studied in vitro [6] and in several pre-
clinical tumor models. scFv78-Fc targeted, shikonin-
loaded PLGA nanoparticles showed higher accumulation
and killing efficacy at the TEM1 positive tumors, com-
pared to free drug and unarmed nanoparticle controls.
Taken together, our data indicate that the scFv78-Fc is
suitable for development as targeted therapeutics and
imaging for cancers such as ovarian cancer and sarcomas.
Based upon these findings, we propose to use the
immuno-imaging for detection and selection of patients
suitable for immune therapies with the TEM1-targeted
immunotoxin or nanoparticles; and for monitoring the
efficacy of such therapies.
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